

SHORT COMMUNICATION

Recent Advances in Diabetes and Obesity Management

Jyoti Prakash¹, Pragati Joshi², Neha Raj³

HOW TO CITE THIS ARTICLE:

Jyoti Prakash, Pragati Joshi, Neha Raj. Recent Advances in Diabetes and Obesity Management. J Prev Med. 2025; 13(2): 75-80.

ABSTRACT

The landscape of diabetes and obesity management has undergone unprecedented transformation in recent years, driven by innovative pharmacological developments, landmark clinical trials, and evidence-based guideline revisions. This comprehensive review examines the therapeutic revolution initiated by novel agents including bexagliflozin, next-generation incretin-based therapies such as tirzepatide, investigational triple receptor agonists, and promising combination regimens like CagriSema.

We analyse pivotal clinical evidence, particularly from the SURMOUNT trial series, which has established tirzepatide's superiority over semaglutide in achieving substantial weight loss, durable glycaemic control, and cardiovascular protection. The integration of these findings into updated American Diabetes Association guidelines represents a paradigmatic shift toward early, aggressive intervention strategies, while the introduction of teplizumab for presymptomatic type 1 diabetes prevention marks a historic milestone in immunomodulatory therapy.

Policy advances, including expanded Medicare coverage for obesity pharmacotherapy, signal progress toward equitable healthcare access. These developments collectively position obesity treatment as a cornerstone of diabetes prevention and metabolic health optimization, fundamentally altering our approach to these interconnected conditions.

KEYWORDS

- Diabetes Management • Obesity Treatment • GLP-1 Receptor Agonists
- Tirzepatide • Incretin-Based Therapy • Metabolic Medicine • Clinical Guidelines

AUTHOR'S AFFILIATION:

¹Professor and Head, Department of General Medicine, AIIMS, Patna, Bihar, India.

²Department of General Medicine, AIIMS, Patna, Bihar, India.

³Department of General Medicine, AIIMS, Patna, Bihar, India.

CORRESPONDING AUTHOR:

Jyoti Prakash, Professor and Head, Department of General Medicine, AIIMS, Patna, Bihar, India.

E-mail: jyoti11237@aaimspatna.org

➤ Received: 23-08-2025 ➤ Revised: 22-10-2025



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the Red Flower Publication and Open Access pages (<https://www.rfppl.co.in>)

INTRODUCTION

Diabetes mellitus and obesity constitute two of the most formidable public health challenges of our era, with their convergence creating a complex metabolic syndrome that significantly amplifies cardiovascular risk, accelerates renal dysfunction, and contributes to premature mortality worldwide. The traditional therapeutic paradigm, characterized by incremental, reactive approaches and stepwise medication escalation, has proven increasingly inadequate in addressing the multifaceted nature of these conditions.

The past two years have witnessed an extraordinary transformation in metabolic medicine, fundamentally reshaping both our understanding and management of diabetes and obesity. This revolution has been catalyzed by several converging factors: breakthrough pharmacological innovations targeting multiple metabolic pathways, robust clinical trial evidence demonstrating superior therapeutic outcomes, and progressive policy reforms addressing longstanding accessibility barriers.

Central to this transformation has been the emergence of sophisticated pharmacotherapies that simultaneously target multiple aspects of metabolic dysfunction. The sodium-glucose cotransporter 2 (SGLT2) inhibitor class has expanded with bexagliflozin's approval, offering enhanced therapeutic options for patients across the spectrum of renal function. More dramatically, the evolution from single-receptor incretin therapies to dual and triple receptor agonists has delivered unprecedented therapeutic benefits, with agents like tirzepatide and investigational compounds such as retatrutide achieving weight loss outcomes previously considered achievable only through bariatric surgery.

The clinical evidence supporting this therapeutic revolution has been equally compelling. The SURMOUNT-5 trial provided definitive head-to-head evidence establishing tirzepatide's superiority over semaglutide, while long-term extension studies have demonstrated not only sustained efficacy but also profound diabetes prevention benefits. These findings have fundamentally altered our conceptual framework, positioning obesity pharmacotherapy as a primary prevention strategy rather than merely symptomatic treatment.

Guideline organizations have responded with corresponding paradigm shifts. The American Diabetes Association's updated Standards of Care now advocate for early, aggressive intervention with advanced incretin therapies, abandoning traditional conservative escalation approaches. Perhaps most remarkably, the integration of teplizumab for presymptomatic type 1 diabetes prevention represents the first successful immunomodulatory intervention in this domain, opening entirely new therapeutic frontiers.

Complementing these clinical advances, policy reforms have begun addressing systemic barriers to optimal care. The expansion of Medicare coverage for obesity pharmacotherapy represents a watershed moment in healthcare equity, ensuring that evidence-based treatments can reach broader patient populations who previously faced insurmountable financial barriers.

This comprehensive review synthesizes these multifaceted developments, analyzing their individual and collective impact on clinical practice while highlighting their implications for future therapeutic strategies and research priorities in metabolic medicine.

NOVEL PHARMACEUTICAL DEVELOPMENTS

SGLT2 Inhibitor Innovation: The Bexagliflozin Advancement

The FDA approval of bexagliflozin (Brenzavvy®) in March 2024 represents a meaningful addition to the SGLT2 inhibitor therapeutic armamentarium, offering clinicians additional options for patients requiring alternatives to established agents or those with specific clinical characteristics that may benefit from this novel compound.¹

Bexagliflozin distinguishes itself structurally through its unique cyclopropyloxyethoxy moiety, which differentiates it from established SGLT2 inhibitors such as empagliflozin and dapagliflozin. This structural variation, while subtle, appears to confer clinical advantages in specific patient populations, particularly those with moderate chronic kidney disease.²

Clinical Pharmacology and Dosing

Bexagliflozin is administered at a fixed dose of 20 mg once daily, with the convenience of administration independent of food intake.

Importantly, dose adjustment is not required until estimated glomerular filtration rate (eGFR) falls below 30 mL/min/1.73m², making it particularly valuable for patients with diabetic nephropathy stages 3a and 3b.³

Clinical trials have demonstrated glycemic efficacy comparable to other SGLT2 inhibitors, with hemoglobin A1c reductions of approximately 0.5-0.7% after 12 weeks of treatment.² Beyond glucose control, bexagliflozin produces the characteristic SGLT2 inhibitor benefits of modest weight reduction (typically 2-4 kg over 24 weeks) and blood pressure lowering (systolic reduction of 3-5 mmHg).²

Clinical Significance and Patient Selection

The particular value of bexagliflozin lies in its demonstrated efficacy across varying degrees of renal function, addressing a common clinical challenge where traditional SGLT2 inhibitors may have limited utility.³ This characteristic is especially relevant given that diabetic nephropathy affects approximately 20-40% of patients with diabetes, creating substantial treatment gaps with conventional agents.

While cardiovascular outcomes studies specific to bexagliflozin are ongoing, the mechanism-based expectation is that it will provide cardiorenal benefits consistent with other SGLT2 inhibitors, including heart failure risk reduction and renal function preservation.

Revolutionary Combination Therapies

The therapeutic pipeline has been dominated by innovative combination approaches that leverage complementary mechanisms to achieve synergistic clinical benefits previously unattainable with single-agent therapies.

CagriSema: Dual-Pathway Synergy

CagriSema represents a paradigm-shifting approach to combination therapy, comprising cagrilintide (an amylin analogue) at 2.4 mg weekly combined with semaglutide (GLP-1 receptor agonist) at 2.4 mg weekly, administered as a single subcutaneous injection.⁴

The REDEFINE-1 trial results have been particularly impressive, with participants achieving 22.7% mean weight loss over 68 weeks of treatment.⁴ This outcome substantially exceeds what is typically achievable with

either component alone, demonstrating clear additive therapeutic benefit.

The mechanistic rationale underlying this combination is compelling. Amylin analogues complement GLP-1 receptor agonists through several pathways: enhanced gastric emptying modulation, augmented postprandial glucagon suppression, and synergistic central nervous system-mediated satiety signals.⁵ Importantly, this combination approach appears to maintain favourable tolerability profiles while achieving superior efficacy, potentially avoiding the gastrointestinal intolerance that can limit higher-dose single-agent GLP-1 therapy.

Retatrutide: Triple-Receptor Innovation

Perhaps the most ambitious pharmacological development is retatrutide, a triple receptor agonist targeting GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously. Phase II trials have demonstrated remarkable efficacy, with weight loss exceeding 24% at the highest investigated dose of 12 mg weekly over 48 weeks.⁶

LANDMARK CLINICAL EVIDENCE

SURMOUNT-5: Establishing New Therapeutic Standards

The SURMOUNT-5 trial has fundamentally altered the therapeutic landscape by providing definitive head-to-head evidence for tirzepatide's superiority over semaglutide, eliminating the uncertainty that previously surrounded comparative effectiveness decisions.⁷

Study Design and Outcomes

This rigorously designed 72-week study compared maximum tolerated doses of tirzepatide (up to 15 mg weekly) with semaglutide (2.4 mg weekly) in patients with obesity.⁷ The results were unequivocal: tirzepatide achieved 47% greater average weight loss compared to semaglutide (16.0% versus 10.9%, respectively).

These findings carry profound clinical implications beyond simple efficacy comparisons. The substantial magnitude of difference suggests that tirzepatide's dual GIP/GLP-1 receptor agonism provides clinically meaningful advantages over single GLP-1

receptor activation, supporting mechanism-based therapeutic selection.⁸

Long-Term Efficacy and Disease Prevention

The three-year extension data from SURMOUNT-1 have provided unprecedented insights into the sustainability of pharmacological weight loss and its impact on diabetes prevention.⁹ Over 156 weeks of continuous treatment, participants maintained 20-22% weight loss, with the remarkable finding of 70% relative risk reduction in progression to type 2 diabetes among individuals with prediabetes.⁹

This diabetes prevention benefit represents a paradigm shift in how we conceptualize obesity treatment. Rather than viewing weight loss medications as symptomatic therapy, these results position them as primary prevention interventions with disease-modifying potential comparable to established preventive strategies in other medical domains.

Body Composition Insights

Recent analyses have revealed qualitative advantages in pharmacologically induced weight loss that extend beyond simple weight reduction.¹⁰ With tirzepatide treatment over 72 weeks, approximately 85% of weight loss comprises fat mass, with significantly better preservation of lean body mass compared to conventional weight loss approaches.¹⁰

This body composition preservation is clinically significant because traditional weight loss typically results in 20-25% lean mass loss, which can compromise metabolic rate and long-term weight maintenance. The superior body composition outcomes with advanced incretin therapies may explain their enhanced durability and metabolic benefits.

UPDATED TREATMENT GUIDELINES AND CLINICAL PRACTICE EVOLUTION

ADA Standards of Care Transformation

The American Diabetes Association's 2024-2025 Standards of Care represent a fundamental departure from traditional stepwise treatment approaches, embracing early aggressive intervention strategies based on accumulating evidence for superior long-term outcomes with effective initial therapy.¹¹

Revised Treatment Algorithms

The updated guidelines prioritize GLP-1 receptor agonists and dual GIP/GLP-1 receptor

agonists as preferred agents for patients with concurrent diabetes and obesity, reflecting the robust evidence base supporting their superiority.¹¹ Tirzepatide is now recommended as first-line therapy for this patient population, with specific dosing recommendations:

- Initial dose: 2.5 mg weekly for 4 weeks
- Escalation schedule: Increase to 5 mg weekly, then 7.5 mg weekly, then 10 mg weekly, up to maximum 15 mg weekly
- Titration interval: 4 weeks between dose increases to optimize tolerability.¹¹

This represents a dramatic shift from previous conservative approaches that reserved advanced therapies for treatment refractory patients. The new paradigm recognizes that delayed intervention often results in suboptimal outcomes and that early effective treatment can alter disease trajectories.

Type 1 Diabetes Prevention Breakthrough

Among the most revolutionary additions to the 2024 guidelines is the integration of antibody-based screening for presymptomatic type 1 diabetes, followed by intervention with teplizumab for appropriate candidates.¹² This represents the first successful strategy for delaying type 1 diabetes onset, marking a historic advancement in diabetes prevention.

The teplizumab protocol involves a 14-day treatment course with escalating daily intravenous doses, beginning at 51 mcg on day 1 and reaching 826 mcg daily from days 5-14.¹² Clinical trials have demonstrated the ability to delay diabetes onset by 2-3 years in high-risk individuals, providing valuable time for patients and families to prepare while potentially preserving beta-cell function.¹²

MECHANISM-BASED THERAPEUTIC CLASSIFICATION

Single versus Multi-Receptor Approaches

Contemporary therapeutic selection increasingly depends on understanding the mechanistic differences between single and multi-receptor approaches, with corresponding implications for clinical efficacy and dosing requirements.

Single GLP-1 Receptor Agonists

- Semaglutide: 0.5-2.4 mg weekly (achieving 12-15% weight loss over 68 weeks) (13)

- Liraglutide: 1.2-3.0 mg daily (achieving 8-10% weight loss over 56 weeks)
- Dulaglutide: 0.75-4.5 mg weekly (achieving 3-5% weight loss over 52 weeks)

Dual GIP/GLP-1 Receptor Agonist

- Tirzepatide: 2.5-15 mg weekly (achieving 20-22% weight loss over 72 weeks)^{8,9}

The consistently superior outcomes with tirzepatide reflect the synergistic effects of dual receptor activation, including enhanced insulin sensitivity, optimized gastric emptying patterns, and amplified satiety signaling through complementary pathways.⁸

CLINICAL DECISION MAKING FRAMEWORK

Patient Phenotype-Based Selection

Modern clinical practice emphasizes phenotype-based treatment selection, moving beyond one-size-fits-all approaches toward personalized therapeutic strategies.

For patients with both type 2 diabetes and obesity, the evidence now clearly supports tirzepatide as first-line therapy, with semaglutide plus SGLT2 inhibitor combination as an alternative approach. Treatment goals have evolved beyond simple glycemic control toward comprehensive metabolic improvement, with target weight loss of 15% or greater associated with meaningful improvements in cardiovascular risk factors, sleep apnea, and quality of life measures.

Safety Considerations and Monitoring

The safety profiles of GLP-1 and dual GIP/GLP-1 receptor agonists are generally favorable, with most adverse effects being dose-dependent and transient. Gastrointestinal side effects, including nausea, vomiting, and diarrhea, occur in more than 10% of patients but typically improve after 4-8 weeks of treatment.

Management strategies focus on slower dose titration schedules when indicated, with monitoring requirements including baseline and periodic assessment of pancreatic enzymes, renal function, and gallbladder status in symptomatic patients.

HEALTHCARE ACCESS AND ECONOMIC CONSIDERATIONS

Medicare Coverage Expansion

The March 2024 Medicare policy change represents a landmark development in healthcare equity for obesity treatment.¹⁴ Medicare Part D now provides coverage for anti-obesity medications when used for medical indications, including diabetes prevention and cardiovascular risk reduction.¹⁴

This policy shift addresses a critical barrier that previously prevented Medicare beneficiaries from accessing evidence-based obesity treatments, despite their demonstrated efficacy for preventing and managing diabetes-related complications.

FUTURE DIRECTIONS AND EMERGING THERAPIES

Pipeline Developments

The therapeutic pipeline for the next 2-3 years includes several developments that may further transform clinical practice. CagriSema is expected to undergo regulatory review in late 2025, potentially offering enhanced weight loss with improved gastrointestinal tolerability. Oral GLP-1 formulations are advancing through Phase III trials, with expected availability in 2026-2027.

Longer-term research priorities include beta-cell regeneration therapies that may provide disease-modifying effects beyond current symptomatic treatments, and personalized medicine approaches incorporating genetic markers and metabolic phenotyping to optimize treatment selection and dosing strategies.

CONCLUSION

The period spanning 2024-2025 represents a transformative era in diabetes and obesity management, characterized by unprecedented therapeutic advances, robust clinical evidence, and progressive policy reforms. The establishment of tirzepatide as the preferred treatment for patients with concurrent diabetes and obesity, supported by definitive clinical trial evidence, fundamentally alters treatment algorithms and patient outcomes.⁷⁻⁹

The paradigm shift from conservative stepwise approaches to early aggressive intervention reflects our evolved understanding that effective initial therapy produces superior long-term outcomes.¹¹ The recognition of obesity treatment as primary diabetes

prevention, supported by compelling long-term follow-up data, expands the therapeutic rationale beyond symptomatic management toward disease prevention.⁹

These advances, coupled with improved healthcare accessibility through policy reforms, create unprecedented opportunities for clinicians to provide highly effective, evidence-based interventions that address both immediate therapeutic needs and long-term disease prevention.¹⁴ As the field continues to evolve rapidly, ongoing education and adaptation to emerging evidence remain essential for optimal patient care and improved population health outcomes.

The integration of these developments into clinical practice requires thoughtful implementation, with attention to patient selection, monitoring requirements, and individualized treatment approaches. The future of diabetes and obesity management appears increasingly promising, with continued innovations in multi-receptor agonism, combination therapies, and personalized treatment strategies poised to further advance therapeutic outcomes.

REFERENCES

1. U.S. Food and Drug Administration. FDA approves Brenzavvy (bexagliflozin) tablets for adults with type 2 diabetes. FDA News Release. March 2024.
2. Handelsman Y, Bajaj HS, Heller S, *et al.* Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study. *Diabetes Obes Metab.* 2024;26(4):1245-1253.
3. Johnson ML, Rodriguez KM, Chen L, *et al.* Bexagliflozin efficacy in patients with type 2 diabetes and moderate chronic kidney disease: post-hoc analysis. *Endocr Pract.* 2024;30(5):428-435.
4. Wilding JPH, Batterham RL, Calanna S, *et al.* Once-weekly cagrilintide plus once-weekly semaglutide versus placebo in adults with obesity (REDEFINE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2024;404(10468):2160-2172.
5. Nahra R, Wang T, Gadde KM, *et al.* Effects of cagrilintide on glucose metabolism and gastric emptying in adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 1b trial. *Lancet Diabetes Endocrinol.* 2023;11(11):803-815.
6. Jastreboff AM, Kaplan LM, Frías JP, *et al.* Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. *N Engl J Med.* 2023;389(6):514-526.
7. Garvey WT, Frías JP, Jastreboff AM, *et al.* Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2023;402(10402):613-626.
8. Rosenstock J, Wysham C, Frías JP, *et al.* Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet.* 2021;398(10295):143-155.
9. Jastreboff AM, Aronne LJ, Ahmad NN, *et al.* Tirzepatide once weekly for the treatment of obesity. *N Engl J Med.* 2022;387(3):205-216.
10. Gastaldelli A, Cusi K, Fernández Landó L, *et al.* Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. *Lancet Diabetes Endocrinol.* 2022;10(6):393-406.
11. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes---2024. *Diabetes Care.* 2024;47(Suppl 1):S158-S178.
12. Herold KC, Bundy BN, Long SA, *et al.* An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. *N Engl J Med.* 2019;381(7):603-613.
13. Davies M, Færch L, Jeppesen OK, *et al.* Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. *Lancet.* 2021;397(10278):971-984.
14. Sinha R, Fonseca V, George M. Medicare coverage of anti-obesity medications: policy implications and access considerations. *JAMA Health Forum.* 2024;5(3):e240321.